Pharmaceutical Commerce Editors

PharmaLex Group, a provider of specialized services for the pharma, biotech and medtech industries, has merged with technology and services organization for clinical and regulatory solutions, Phlexglobal.

Phlexglobal offers its electronic Trial Master File platform (PhlexTMF) and services to a plethora of global life sciences companies and artificial intelligence (AI)-enabled automation solutions that allow clients to benefit from existing clinical and regulatory training models.

“We are delighted to welcome the Phlexglobal team to the PharmaLex Group, and the opportunity to continue our commitment to innovation by further expanding our technology-enabled service solutions portfolio with the addition of Phlexglobal’s capabilities for eTMF technology and services, as well as their state-of-the-art regulatory operations and automation technologies,” said Thomas Dobmeyer, PharmaLex CEO, in a Jan. 25, 2022 press release. “The merger enables us to further our goal of becoming a technology-enabled solution provider, and at the same time increasing operational excellence and efficiency through our global subject matter expertise.”

Articles

Merger with Phlexglobal expands provider’s technological capabilities.